Find Therapeutics Doses First Subject in Phase I Trial of FTX-101 for Chronic Optic Neuropathy
核心洞察
Find Therapeutics initiated a Phase I clinical trial of FTX-101, a potential treatment for chronic optic neuropathy (搜索), after receiving FDA approval.
The Phase I trial is a two-part study evaluating the safety, tolerability, and pharmacokinetics of FTX-101 versus placebo in healthy volunteers.
FTX-101 is designed as a remyelinating agent that could restore vision by addressing demyelination in the visual pathways.
Find Therapeutics, a Canadian biopharmaceutical company, has dosed the first subject in a Phase I clinical trial of its lead compound, FTX-101, as a potential treatment for chronic optic neuropathy (搜索). The trial, a two-part study, received approval from the US Food and Drug Administration (FDA) earlier this year and aims to evaluate the safety, tolerability, and pharmacokinetics of FTX-101 compared to placebo in healthy volunteers. This marks a significant milestone for Find Therapeutics in its pursuit of developing innovative therapies for inflammatory autoimmune diseases.
The Phase I trial is structured into two parts: a double-blind, randomized, placebo-controlled, single-ascending dose (SAD) study involving 40 subjects, and a multiple-ascending dose (MAD) study enrolling 24 subjects. Find Therapeutics anticipates releasing data from the trial in the first half of next year.
FTX-101: A Remyelinating Agent
FTX-101 is designed as a remyelinating agent with the potential to restore vision for individuals suffering from chronic optic neuropathy (搜索), a condition characterized by demyelination in the visual pathways. Preclinical data have demonstrated strong myelin repair activity, suggesting that FTX-101 could offer a novel approach to treating this debilitating condition.
The therapeutic peptide modulates the Plexin A1 (搜索) / Neuropilin 1 (搜索) receptor complex in the brain to promote remyelination.
Management Perspective
"The initiation of this study is a significant milestone for both our company and individuals who suffer from chronic optic neuropathy (搜索)," said Philippe Douville, CEO of Find Therapeutics. "In this study, we will build on the large body of preclinical evidence demonstrating FTX-101’s effects in models of autoimmune disease. A therapy of this type would represent a major step forward in finding the first treatment to improve the lives of people afflicted with chronic optic neuropathy."
About Find Therapeutics
Founded in 2020, Find Therapeutics is focused on developing next-generation therapies for inflammatory autoimmune diseases. The company has garnered support from CTI Life Sciences, adMare BioInnovations, Domain Therapeutics, Investissment Québec, SATT-Conectus, and the University of Strasbourg. Last month, Find Therapeutics raised C$11 million ($8.1 million) in a convertible note financing round to advance FTX-101 into Phase I clinical studies.